Table 1 Combined therapeutic outcomes of cis mAb treatments in ssTBI mice or rmTBI mice regimens
TBI-related outcomes | Experimental tests | Treatment regimen (as used in figures) | No of total mice used | No of mice each group | Pathological and functional outcomes (fold ± SD) | Cohen’s d* or z -score effect size** | p -value | |||
|---|---|---|---|---|---|---|---|---|---|---|
Combined IgG/Sham | Combined Cis mAb/ Sham | Cis mAb combined effect size | ||||||||
Selected pathological outcomes | ||||||||||
Cis P-tau | Cis P-tau (cortex) | 5a; 4a; 7a | 39 | 3−4 | 100.7 ± 0.28 | 11.3 ± 0.25 | 8.91 ± 0.36 | 5.99 | ≤0.0001 | |
Cis P-tau (hippo.) | 5a; 4a; 7a | 39 | 3−4 | 67.8 ± 0.88 | 5.87 ± 0.19 | 11.5 ± 0.91 | 1.98 | ≤0.0001 | ||
Trans P-tau | Trans P-Tau (cortex) | 5a; 4a; 7a | 39 | 3−4 | 1.00 ± 0.22 | 1.00 ± 0.21 | 1.00 ± 0.23 | 0.02 | >0.05 | |
Trans P-Tau (hippo.) | 5a; 4a; 7a | 39 | 3−4 | 1.04 ± 0.24 | 1.03 ± 0.26 | 1.01 ± 0.21 | 0.03 | >0.05 | ||
Axonal injury | Gallyas silver (cortex) | 5a; 4a; 7a | 39 | 3−4 | 20.8 ± 6.51 | 1.66 ± 0.58 | 12.5 ± 6.51 | 2.26 | ≤0.0001 | |
Gallyas silver (hippo.) | 5a; 4a; 7a | 39 | 3−4 | 15.2 ± 4.65 | 1.46 ± 0.56 | 10.5 ± 4.67 | 2.21 | ≤0.0001 | ||
Other tau pathology | T22 (cortex) | 5a; 4a; 7a | 39 | 3−4 | 81.8 ± 0.81 | 8.98 ± 0.22 | 9.12 ± 0.83 | 2.09 | ≤0.0001 | |
T22 (hippocampus) | 5a; 4a; 7a | 39 | 3−4 | 64.4 ± 0.85 | 5.85 ± 0.21 | 11.0 ± 0.87 | 1.93 | ≤0.001 | ||
AT8 (cortex) | 5a; 4a; 7a | 39 | 3−4 | 69.0 ± 0.84 | 12.3 ± 0.27 | 5.63 ± 0.89 | 1.75 | ≤0.0001 | ||
AT8 (hippocampus) | 5a; 4a; 7a | 39 | 3−4 | 63.8 ± 0.81 | 7.16 ± 0.22 | 8.91 ± 0.87 | 1.85 | ≤0.0002 | ||
AT100 (cortex) | 5a; 4a; 7a | 39 | 3−4 | 59.8 ± 0.84 | 7.39 ± 0.22 | 8.08 ± 0.86 | 1.71 | ≤0.0001 | ||
AT100 (hippocampus) | 5a; 4a; 7a | 39 | 3−4 | 60.2 ± 0.80 | 6.56 ± 0.21 | 9.18 ± 0.81 | 1.86 | ≤0.0003 | ||
APP accumulation | APP (cortex) | 5a; 4a; 7a | 39 | 3−4 | 3.82 ± 0.43 | 1.39 ± 0.19 | 2.74 ± 0.46 | 2.09 | ≤0.0001 | |
APP (hippocampus) | 5a; 4a; 7a | 39 | 3−4 | 2.59 ± 0.46 | 1.12 ± 0.12 | 2.30 ± 0.45 | 1.47 | ≤0.006 | ||
Neuron inflammation | GFAP (cortex) | 5a; 4a; 7a | 39 | 3−4 | 1.62 ± 0.13 | 1.06 ± 0.03 | 1.52 ± 0.14 | 1.68 | ≤0.0005 | |
GFAP (hippocampus) | 5a; 4a; 7a | 39 | 3−4 | 1.42 ± 0.11 | 1.03 ± 0.02 | 1.37 ± 0.11 | 1.51 | ≤0.001 | ||
Selected functional outcomes | ||||||||||
Sensorimotor coordination defects | Ledge test | 4a, b; 5a; 6a, b; 7a | 99 | 5−9 | 2.92 ± 0.38 | 1.06 ± 0.19 | 2.74 ± 0.49 | 0.64** | ≤0.0001 | |
String suspension | 4a, b; 5a; 6a, b; 7a | 99 | 5−9 | 3.32 ± 0.66 | 1.00 ± 0.24 | 3.34 ± 0.81 | 0.56** | ≤0.0001 | ||
Accelerating rotarod | 7a | 27 | 9 | 1.22 ± 0.05 | 0.90 ± 0.03 | 1.35 ± 0.04 | 1.22 | ≤0.03 | ||
Cognitive loss | Novel location recog. | 7a | 27 | 9 | 1.27 ± 0.05 | 0.91 ± 0.03 | 1.38 ± 0.05 | 1.21 | ≤0.03 | |
Urinary control | Voiding pattern | 5a; 7a | 42 | 5-9 | 1.45 ± 0.09 | 0.93 ± 0.06 | 1.56 ± 0.10 | 0.55** | ≤0.002 | |
